Figure 6: Compound 2 improves DM1-like splicing defects induced in HeLa cells.
From: Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules
(a) Compound 2 improves dysregulation of IR alternative splicing in a DM1 model cellular system. (a, top) Representative gel image of IR alternative splicing in the presence of varying concentrations of 2. (a, bottom) Quantification of exon inclusion for IR alternative splicing in the presence or absence of r(CUG)exp and 2 (n≥3). Error bars are the s.d. values in the measurements. (b) Compound 2 improves dysregulation of cTNT alternative splicing in a DM1 model cellular system. (b, top) Representative gel image of cTNT alternative splicing in the presence of varying concentrations of 2. (b, bottom) Quantification of exon inclusion for cTNT alternative splicing in the presence or absence of r(CUG)exp and 2 (n≥3). Error bars are the s.d. values in the measurements. The percentage of each isoform was determined by RT–PCR using a radioactively labelled forward PCR primer. ‘**’ indicates P≤0.01 as determined by a two-tailed Student’s t-test.
